Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16

被引:45
作者
Woodworth, Craig D. [1 ]
Diefendorf, Laura P. [1 ]
Jette, David F. [1 ]
Mohammed, Abdulmajid [1 ]
Moses, Michael A. [1 ]
Searleman, Sylvia A. [1 ]
Stevens, Dan A. [1 ]
Wilton, Katelynn M. [1 ]
Mondal, Sumona [2 ]
机构
[1] Clarkson Univ, Dept Biol, Potsdam, NY 13699 USA
[2] Clarkson Univ, Dept Math, Potsdam, NY 13699 USA
关键词
Epidermal growth factor receptor; Erlotinib; Immortalization; Apoptosis; Senescence; Papillomavirus; Cervical cancer; Chemoprevention; TYROSINE KINASE INHIBITOR; PHASE-II TRIAL; HUMAN KERATINOCYTES; EPITHELIAL-CELLS; LUNG-CANCER; MESSENGER-RNA; MOLECULAR TARGETS; E5; ONCOPROTEIN; CHEMOPREVENTION; CARCINOMA;
D O I
10.1016/j.virol.2011.09.014
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
The Human Papillomavirus type-16 (HPV-16) E6 and E7 oncogenes are selectively retained and expressed in cervical carcinomas, and expression of E6 and E7 is sufficient to immortalize human cervical epithelial cells. Expression of the epidermal growth factor receptor (EGFR) is often increased in cervical dysplasia and carcinoma, and HPV oncoproteins stimulate cell growth via the EGFR pathway. We found that erlotinib, a specific inhibitor of EGFR tyrosine kinase activity, prevented immortalization of cultured human cervical epithelial cells by the complete HPV-16 genome or the E6/E7 oncogenes. Erlotinib stimulated apoptosis in cells that expressed HPV-16 E6/E7 proteins and induced senescence in a subpopulation of cells that did not undergo apoptosis. Since immortalization by HPV E6/E7 is an important early event in cervical carcinogenesis, the EGFR is a potential target for chemoprevention or therapy in women who have a high risk for cervical cancer. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 49 条
[1]
Akerman GS, 2001, CANCER RES, V61, P3837
[2]
How to evaluate emerging technologies in cervical cancer screening? [J].
Arbyn, Marc ;
Ronco, Guglielmo ;
Cuzick, Jack ;
Wentzensen, Nicolas ;
Castle, Philip E. .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (11) :2489-2496
[3]
Absence of epidermal growth factor receptor mutations in cervical cancer [J].
Arias-Pulido, H. ;
Joste, N. ;
Chavez, A. ;
Muller, C. Y. ;
Dai, D. ;
Smith, H. O. ;
Verschragen, C. F. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (04) :749-U4
[4]
Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442
[5]
Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells [J].
Budiyanto, A ;
Bito, T ;
Kunisada, M ;
Ashida, M ;
Ichihashi, M ;
Ueda, M .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 121 (05) :1088-1094
[6]
Papillomavirus Prophylactic Vaccines: Established Successes, New Approaches [J].
Campo, M. Saveria ;
Roden, Richard B. S. .
JOURNAL OF VIROLOGY, 2010, 84 (03) :1214-1220
[7]
Small-molecule inhibitors of the human epidermal receptor family [J].
Carter, Corey A. ;
Kelly, Ronan J. ;
Giaccone, Giuseppe .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (12) :1829-1842
[8]
Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions [J].
Chen, Helen X. ;
Cleck, Jessica N. ;
Coelho, Rochelle ;
Dancey, Janet E. .
CURRENT PROBLEMS IN CANCER, 2009, 33 (04) :245-+
[9]
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer [J].
Goncalves, A. ;
Fabbro, M. ;
Lhomme, C. ;
Gladieff, L. ;
Extra, J. -M. ;
Floquet, A. ;
Chaigneau, L. ;
Carrasco, A. Tisseron ;
Viens, P. .
GYNECOLOGIC ONCOLOGY, 2008, 108 (01) :42-46
[10]
Targeting Multiple Kinase Pathways: A Change In Paradigm [J].
Gossage, Lucy ;
Eisen, Tim .
CLINICAL CANCER RESEARCH, 2010, 16 (07) :1973-1978